The University Hospital Würzburg is inviting applications for

**junior group leader positions and tenure track positions**

in the field of T-cell engineering and cancer immunotherapy.

The University Hospital Würzburg has established a leading translational research program on CAR T-cell immunotherapy in Europe. The program is led by Prof. Michael Hudecek and Prof. Hermann Einsele. The scope of the program encompasses basic research on fundamental issues of immune cell function and signaling, target antigen discovery and characterization, receptor and protein engineering; as well as translational and clinical research, including first-in-man clinical trials with novel CAR T-cell and other gene-modified immune cell products.

The program is embedded into an excellent scientific research and clinic environment in Würzburg, with a dense network to other KOLs within Germany, Europe and beyond.

The program is looking to expand and secure leadership through scientific excellence and innovative 'out of the box' approaches. We therefore invites scientists and physicians to establish their research groups within the nurturing environment of the CAR T-cell immunotherapy program in Würzburg after a successful training period in the US.

**Keywords:** chimeric antigen receptor (CAR), gene engineering, cellular immunotherapy, cancer immunotherapy, protein engineering, artificial intelligence

**Contact:**
Univ. Prof. Dr. med. Michael Hudecek  
Hudecek_M@ukw.de  
https://www.ukw.de/medizinische-klinik-ii/forschung/t-zell-engineering/

Leiter CAR-T Forschungsprogramm  
Zelluläre Immuntherapie von malignen Erkrankungen  
Max Eder Forschungsgruppe „CAR T-cell engineering“  
Universitätsklinikum Würzburg  
Medizinische Klinik und Poliklinik II  
Oberdürrbacherstrasse 6  
97080 Würzburg